Rhythm Pharmaceuticals officer proposes $5.35M stock sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Joseph J. Shulman, an officer of Rhythm Pharmaceuticals, Inc. (RYTM), reported a proposed sale of 45,921 common shares with an aggregate market value of $5,354,847.81, with an approximate sale date of November 18, 2026. The acquisition table lists 40,467 shares acquired through stock-option exercise on November 18, 2026 and 5,454 restricted stock units acquired February 1, 2025; the remarks separately state that the securities to be sold were acquired upon restricted-stock-unit vesting from February 1 through February 16, 2025.
Key Figures
Key Terms
Exercise of Stock Options financial
Restricted Stock Units financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Rule 10b5-1 date is listed for Joseph J. Shulman's RYTM sale notice?
AI-generated analysis. How Rhea-AI works. Not financial advice.